Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States

Journal of Medical Economics

Volumn 15, Issue 2, 2012, Pages 264-275

  Schabert, Vernon F ^a   Watson, Crystal ^b   Gandra, Shravanthi R ^b   Goodman, Seth ^a   Fox, Kathleen M ^c   Harrison, David J ^b  

^a IQVIA   (United States)

^b AMGEN INC   (United States)

^c Strategic Healthcare Solutions LLC   (United States)

Author keywords

Adalimumab; Ankylosing spondylitis; Cost; Etanercept; Infliximab; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; COST OF ILLNESS; DATA BASE; DRUG COST; DRUG DOSE REGIMEN; DRUG INDICATION; DRUG SUBSTITUTION; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UNITED STATES;

ADULT; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DRUG COSTS; FEMALE; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, HEALTH; MALE; MIDDLE AGED; PRESCRIPTION FEES; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84858130634     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.644645     Document Type: Article

References (23)

1. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008;9:52
2. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008;148:124-34 (Pubitemid 351651555)
3. Kristensen LE, Christensen R, Bliddal H, et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. Scand J Rheumatol 2007;36:411-7 (Pubitemid 350293516)
4. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009;181:787-96
5. Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology 2009;219:209-18
6. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008;159:513-26
7. Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2008;35:883-90 (Pubitemid 351747132)
8. McLeod C, Bagust A, Boland A, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-158, iii-iv
9. Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic doseescalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
10. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
11. Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-812.
12. Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-5 (Pubitemid 41745946)
13. Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
14. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21-7 (Pubitemid 40740522)
15. Gilbert Jr TD, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
16. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53 (Pubitemid 44476656)
17. Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken) 2010;62:1335-41
18. Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation in rheumatoid arthritis patients treated with tumor necrosis factor blockers: a comparative effectiveness analysis. Prague, Czech Republic: ISPOR European Congress, 2010
19. Segal SD, Power DJ, Smith DB, et al. Comparative effectiveness analysis of TNF blockers in rheumatoid arthritis patients in US Community Practice. London: EULAR, 2011
20. Bonafede RP, Chastek B, Becker L, et al. Comparative effectiveness analysis of TNF blockers in rheumatoid arthritis (RA) patients in a real-world setting. ISPOR 16th Annual International Meeting. Baltimore, MD: ISPOR 16th Annual International Meeting, 2011
21. Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:825-35
22. Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-46 (Pubitemid 351563994)
23. Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007;23:1749-59 (Pubitemid 47300371)